Explore the words cloud of the VSV-EBOVAC project. It provides you a very rough idea of what is the project "VSV-EBOVAC" about.
The following table provides information about the project.
SCLAVO VACCINES ASSOCIATION
|Coordinator Country||Italy [IT]|
|Total cost||4˙786˙010 €|
|EC max contribution||3˙887˙260 € (81%)|
1. H2020-EU.18.104.22.168. (Other)
|Duration (year-month-day)||from 2015-03-01 to 2019-02-28|
Take a look of project's partnership.
|1||SCLAVO VACCINES ASSOCIATION||IT (SIENA)||coordinator||841˙250.00|
|2||GOETEBORGS UNIVERSITET||SE (GOETEBORG)||participant||700˙000.00|
|3||EMORY UNIVERSITY NON PROFIT CORP||US (Atlanta)||participant||600˙888.00|
|4||UNIVERSITA DEGLI STUDI DI SIENA||IT (SIENA)||participant||562˙500.00|
|5||ACADEMISCH ZIEKENHUIS LEIDEN||NL (LEIDEN)||participant||522˙552.00|
|6||MICROBIOTEC SRL||IT (MONTERIGGIONI)||participant||212˙500.00|
|7||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||131˙820.00|
|8||Department of Health||UK (Leeds)||participant||125˙000.00|
|9||Centre de Recherches Medicales de Lambaréné||GA (Lambaréné)||participant||118˙875.00|
|10||BIOPROTECTION SYSTEMS CORPORATION||US (AMES)||participant||62˙500.00|
|11||EBERHARD KARLS UNIVERSITAET TUEBINGEN||DE (TUEBINGEN)||participant||9˙375.00|
|12||EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT||CH (BERN)||participant||0.00|
|13||UNIVERSITE DE GENEVE||CH (GENEVE)||participant||0.00|
The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promising new Ebola vaccine candidate, the vesicular stomatitis virus (VSV)â€ vectored Zaire Ebola vaccine (VSV-ZEBOV). In non-human primates, a single dose of VSV-ZEBOV elicited a strong (100%) and long-lasting protective efficacy against Ebola Zaire infections. Developed by Public Health Canada and manufactured by NewLink Genetics, VSV-ZEBOV was thus selected by the World Health Organization (WHO) as one of the 2 most promising vaccine candidates. To accelerate its clinical development, the WHO has organized a consortium and supported the organization of parallel first-in-man Phase I/II clinical trials, both in Europe and Africa. The primary objectives of these trials, initiated mid-November 2014, are to study the safety and antibody-inducing capacity of various doses of VSV-ZEBOV in European and African populations.
We propose to build upon this asset to acquire new and critical knowledge of the innate and adaptive immune responses elicited in humans by VSV-ZEBOV vaccination, with specific emphasis on trancriptomics and metabolomics signatures. To this aim, we have constructed a consortium including representatives from the vaccine manufacturer, scientists of the 3 main clinical sites (Switzerland, Gabon, Kenya) and world-leaders in immunology and partners of ADITEC, a large FP7- supported collaborative research programme aiming to accelerate the development of novel, powerful immunisation technologies for next-generation vaccines. We propose an ambitious program using cutting-edge technologies to perform an in depth characterization of the clinical samples harvested before/after VSV-ZEBOV immunization of 200 volunteers in Switzerland, Gabon and Kenya, and to extend the recently initiated clinical studies up to 12 months to identify the signatures and determinants of persistent immune responses.
|Predictive correlates of protective immunity and safety determined.||Documents, reports||2019-10-01 09:22:26|
|Establishment of the External Advisory Board||Documents, reports||2019-06-19 17:57:00|
|Distribution of early samples (day 0-14) to partners involved in immunogenicity studies||Documents, reports||2019-06-19 17:57:00|
|Distribution of intermediate samples (day 28) to partners involved in immunogenicity studies||Documents, reports||2019-06-19 17:57:00|
|Web site development and maintenance||Websites, patent fillings, videos etc.||2019-06-19 17:57:00|
|Distribution of late samples (> day 28) to partners involved in immunogenicity studies||Documents, reports||2019-06-19 17:57:00|
Take a look to the deliverables list in detail: detailed list of VSV-EBOVAC deliverables.
|year||authors and title||journal||last update|
Donata Medaglini, Claire-Anne Siegrist
Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine
published pages: 88-94, ISSN: 1879-6257, DOI: 10.1016/j.coviro.2017.03.008
|Current Opinion in Virology 23||2019-06-19|
Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, JosÃ© F Fernandes, Emmanuel Bache Bache, Lumeka Kabwende, Francis Maina Ndungu, Jessica Brosnahan, Thomas P Monath, Barbara LemaÃ®tre, StÃ©phane Grillet, Miriam Botto, Olivier Engler, Jasmine Portmann, Denise Siegrist, Philip Bejon, Peter Silvera, Peter Kremsner, Claire-Anne Siegrist, Sanjeev KRISHNA, Marylyn M. ADDO, Stephan BECKER, Verena KRÃ„HLING, Patricia NJUGUNA, Marie-Paule KIENY, Rafi AHMED, Jenna ANDERSON, Floriane AUDERSET, Luisa BORGIANNI, Annalisa CIABATTINI, Marielle C. HAKS, Ali HARANDI, Donald Gray HEPPNER, Alice GERLINI, Donata MEDAGLINI, Tom H.M. OTTENHOFF, David PEJOSKI, Mark PAGE, Gianni POZZI, Francesco SANTORO, Sheri DUBEY, JosÃ© F. FERNANDES, Helder NAKAYA, Fiona OROURKE, Gianni POZZI, Sylvia ROTHENBERGER
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
published pages: 738-748, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(18)30165-8
|The Lancet Infectious Diseases 18/7||2019-06-19|
Angela Huttner, Claire-Anne Siegrist
Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
published pages: 1105-1110, ISSN: 1476-0584, DOI: 10.1080/14760584.2018.1546582
|Expert Review of Vaccines 17/12||2019-06-19|
Angela Huttner, Christophe Combescure, StÃ©phane Grillet, MariÃ«lle C. Haks, Edwin Quinten, Christine Modoux, Selidji Todagbe Agnandji, Jessica Brosnahan, Julie-Anne Dayer, Ali M. Harandi, Laurent Kaiser, Donata Medaglini, Tom Monath, Pascale Roux-Lombard, Peter G. Kremsner, Tom H. M. Ottenhoff, Claire-Anne Siegrist
A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa
published pages: eaaj1701, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aaj1701
|Science Translational Medicine 9/385||2019-06-19|
Donata Medaglini, Francesco Santoro, Claire-Anne Siegrist
Correlates of vaccine-induced protective immunity against Ebola virus disease
published pages: 65-72, ISSN: 1044-5323, DOI: 10.1016/j.smim.2018.07.003
|Seminars in Immunology 39||2019-06-19|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VSV-EBOVAC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "VSV-EBOVAC" are provided by the European Opendata Portal: CORDIS opendata.
Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854Read More
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842Read More
Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890Read More